This approach enables the more precise selection of anti-inflammatory treatments and helps prioritize agents that will directly impact disrupted molecular pathways, offering a more targeted approach to MOG optic neuritis management and improving patient outcomes by reducing optic nerve atrophy. Here, MOG is linked to optic neuritis.